The role of tumor cell membrane gangliosides in tumor formation was probed using a series of cloned murine AKR lymphoma cell lines. Tumor formation was directly related to high expression and shedding of membrane gangliosides. In vivo, as little as I pmol of purified total gangliosides of highly tumorigenic cells, injected intradermally with poorly tumorigenic cells (which lacked and did not shed gangliosides), markedly increased the tumorigenicity of these cells in syngeneic normal mice. Thus, gangliosides shed by tumor cells are a previously unrecognized, extremely potent enhancer of tumor formation in vivo.
Introduction
Tumor formation is a complex process, influenced by multiple factors. Among these, transformation and tumorigenicity are two phenotypic characteristics ofcell lines that are under separate genetic control (1) . Transformation indicates that a cell line is "immortalized"; capable of proliferating independently and indefinitely in vitro. In contrast, tumorigenicity demands that transformed cells proliferate in vivo, resist elimination by the syngeneic normal host, and form progressively growing tumors. It is highly likely that local tumor cell-host interactions influence the initial steps of tumor formation in vivo. Relatively little experimental attention has been given, however, to the shedding (2, 3) of membrane molecules such as gangliosides into the immediate extracellular environment ofthe tumor cell, and to the possible effects of these shed molecules on tumorigenicity.
Gangliosides are complex glycosphingolipids found primarily on the external membrane of cells, and some gangliosides are markers of development and oncogenesis (4) (5) (6) (7) . Our interest in this class of molecules, with respect to tumor formation, stems from the fact that tumor-derived gangliosides are potent inhibitors of the cellular immune response in vitro (8, 9) , and are shed by tumor cells (8, 10) . We hypothesized that quantitative aspects of the shedding of these biologically active molecules might modulate tumor formation, possibly by abrogating host anti-tumor immune responses (8) . Some correlations between tumor cell ganglioside content and tumor formation (11) (12) (13) (14) (15) (16) support this possibility, but to date there has been no direct proof that tumor cell gangliosides influence tumorigenicity (6) .
To test this hypothesis, we have studied a murine lymphoma from which several cell lines of markedly different tumorigenic potential had been cloned. Our experiments correlate ganglioside shedding and tumorigenicity, and show that very small quantities ofgangliosides synthesized and shed by tumor cells can markedly augment the tumorigenicity of poorly tumorigenic, gangliosidedeficient tumor cells. These findings suggest that tumor-derived gangliosides play an important physiologic role in the enhancement of tumor formation.
Methods
Tumor cell lines. The cell lines studied are all clones of spontaneous lymphoma 12 (SL12), a heterogeneous cell line isolated from a thymic lymphoma arising in an AKR mouse (17) . These cell lines, SL12.1, SL12.3, and SL12.4, were chosen for the present study because of their previously determined markedly different tumorigenic potentials. Surface markers and other characteristics of the three clones (which were kindly provided by C. MacLeod) have been described elsewhere (17) . All cell lines were free of infection by mycoplasma. The three cell lines had very similar doubling times and saturation densities in vitro (12-15 h and 5 X 106 cells/ml, respectively), suggesting that the differences in tumorigenicity among these three lines were not due to different intrinsic proliferative characteristics, but related to differences in the physiology of tumor formation.
Ganglioside purification. Gangliosides were purified from the total lipid extract (8) of 0.5-2 X 109 cells for each determination of total ganglioside content. The gangliosides were purified by partitioning the dried total lipid extract in diisopropyl ether/l-butanol/50 mM aqueous NaCI, 6/4/5 (vol/vol/vol) (18) . The resulting (ganglioside-containing) aqueous phase was further purified by Sephadex G-50 gel filtration, as described (18) , to remove salts and other low molecular weight contaminants. The purified total gangliosides thus obtained were quantitated as nmol lipid-bound sialic acid (LBSA)' by the modified resorcinol method (19).
Thin-layer chromatography. Thin-layer chromatographic (TLC) analysis ofgangliosides was performed as previously described (8) New England Nuclear, Boston, MA) per ml culture medium (22) . The cells were then washed to remove free label, and an aliquot taken to determine the specific activity of the radiolabeled gangliosides. The remaining cells were resuspended in fresh medium and cultured for an additional 24 h to determine the disappearance from the cells, and the appearance in the culture supernatant, of ganglioside-associated radioactivity. Gangliosides were purified from the cells and their culture supernatant as described above, with the addition of 20 nmol unlabeled purified brain gangliosides to each sample as carrier molecules for the purification procedure. Ganglioside-associated radioactivity was quantitated by #-scintillation counting.
Tumor formation. To assess the role of gangliosides in modulating tumor formation, we used the highly tumorigenic SLI2.3 cells and the poorly tumorigenic ganglioside-deficient SL12.4 cells. Tumor cells were injected intradermally to optimize the intercellular and cellular-extracellular environmental interactions that might in turn modulate the process of tumor formation. In syngeneic mice the tumors were 3-5 mm in diameter within 2 wk, and all tumors grew progressively with time. Intradermal injection of between 2 and 3 X 103 SL12.3 cells yielded tumors in 50% of the mice. In contrast, I0 ganglioside-deficient SL12.4 cells were needed to give the same tumor incidence.
Results
Ganglioside expression. Total ganglioside content of the three clones cultured in vitro varied more than 100-fold (0.5 to 71 nmol LBSA/109 cells, Table I ). There was a direct correlation between the concentration of cell membrane gangliosides and the previously determined ability of the cells to form tumors in vivo (Table I ). Clone SL12.3, with the highest total ganglioside content, required injection of the lowest number of cells (103) to yield a 50% tumor incidence. In contrast, clone SL12.4, virtually deficient in gangliosides, required a 1,000-fold higher number ofcells to yield the same tumor incidence. Clone SL12.1 was intermediate both in ganglioside content and in tumorigenicity. Thus, striking differences in tumorigenicity correlated directly with striking differences in ganglioside content.
Ganglioside shedding. Shedding of significant quantities of gangliosides by highly tumorigenic cells into their extracellular environment is predicted by the hypothesis that tumor cell gangliosides interfere with host responses to tumor. We quantitated this shedding process and found the highly tumorigenic SL12.3 clone to shed 18 pmol gangliosides/106 cells per 24 h. The rate was dramatically less (0.2 pmol/106 cells per 24 h) in the poorly tumorigenic SL12.4 clone (Table II) . Like ganglioside content, ganglioside shedding thus differed markedly in these two clones, and tumorigenicity correlated with the ganglioside shedding rate.
The cellular and shed gangliosides ofclone SL12.3 are shown in Fig. 1 . The resorcinol-stained (Fig. 1 a) and the radiolabeled (Fig. 1 b) cellular ganglioside patterns were quantitatively and qualitatively nearly identical. (The minor ganglioside band below (Fig. 1 b) were also recovered from the culture supernatant ( Fig. 1 c) , confirming their shedding by the SL12.3 cells, as established quantitatively in Table II . In contrast, the poorly tumorigenic (ganglioside deficient) SL12.4 cells contained and shed insufficient quantities of gangliosides to be detectable by HPTLC. Enhancement oftumorigenicity by gangliosides. The purified total gangliosides of the highly tumorigenic SL12.3 cells were used to directly test the influence of ganglioside expression and shedding on tumorigenicity. These gangliosides are shown in Fig. 1 a and are recognized by their characteristic purple staining with resorcinol reagent (19). If shed gangliosides "protect" tumor cells from host destruction, then the co-injection of these gangliosides with the poorly tumorigenic, ganglioside-poor SL12.4 cells should promote tumor formation by SL12.4 cells. To test this, 0.1 pmol to 10 pmol purified total gangliosides from SL12.3 cells were injected intradermally together with 5 X I04 SL12.4 cells. This number ofcells, when injected alone, yielded a tumor incidence, at 2 wk, of 8% (1 of 12 syngeneic normal mice in two separate experiments, Table III ). In contrast, the tumor incidence increased to 83% when as little as 1 pmol of the gangliosides was injected together with the SL12.4 cells ( Table III) (17) , all of 10 mice immunosuppressed by 400 rad total body irradiation developed tumors after the i.v. injection of 1 X 106 SLI2.4 cells versus only a 50% tumor incidence in unirradiated (control) mice (P < 0.05). Second, intraperitoneal pretreatment of mice with 150 mg silica gel, which inhibits macrophage tumoricidal activity (23), increased the incidence of tumor formation by 1 X 106 SL12.4 cells (injected intravenously 48 h later) to 90% (18 of 20 mice) from 43% (13 of 30 mice) in the control group (P < 0.005). These results indirectly suggest that the mechanism of the protective action of SL12.3 cell gangliosides could be to block host anti-tumor immune responses.
Synergism in tumorformation by highly and poorly tumorigenic cells. A final series of experiments show that the SL12.3 cells which shed gangliosides exerted a tumor-protective activity for the poorly tumorigenic ganglioside-deficient SL12.4 clone. These experiments tested for synergy in tumor formation by highly and poorly tumorigenic cells. The reason for this is that a small number of the protective SLI2.3 cells are injected together with a nontumorigenic number (1 X 104) ofSL12.4 cells. If the biologically important difference between the two cell lines is the shedding of gangliosides, gangliosides shed by the SL12.3 cells might protect the SL12.4 cells from host destruction, rendering all ofthe total ofslightly more than I04 cells tumorigenic.
The results (Table IV) 
Discussion
This study demonstrates that the in vivo administration of purified total gangliosides shed by tumor cells enhances tumor formation. Using two distinct strategies to provide tumor-derived gangliosides to the local environment ofthe poorly tumorigenic cells that are deficient in gangliosides, tumor formation was markedly increased. These experiments simulate the natural bi- Consideration of quantitative aspects ofganglioside shedding further supports the conclusion that shed membrane gangliosides enhance the tumorigenicity of transformed cells. As little as 1 pmol SL12.3 cell gangliosides produced optimal effects. This clone contains 3.6 pmol gangliosides/5 X I04 cells, of which 0.9 pmol/24 h are shed (calculated from Tables I and II) . We therefore injected only as much gangliosides as the equivalent number of highly tumorigenic cells shed in one day. Tumor-promoting activity thus resulted from the presence of biologically relevant quantities of ganglioside.
Tumor formation by the poorly tumongenic SL12.4 cells was also enhanced when immunosuppressed rather than immunologically intact mice were used as hosts. We postulate that the addition ofgangliosides protected the SL12.4 cells from host immune destruction. Whether tumor gangliosides block immunological surveillance (24) remains to be proven, and to be distinguished from a possible effect of added ganglioside on the ganglioside-deficient cells themselves. It seems possible, however, for the following reasons: (a) Gangliosides inhibit the in vitro function oflymphocytes (8, 9, (25) (26) (27) (28) , monocytes (29) , and natural killer cells (30 (8, 9, (25) (26) (27) (28) (29) (30) will form a tumor in a normal syngeneic host and may constitute a mechanism contributing to tumor progression. Our findings may be directly relevant to human cancer since it has already been shown that one aggressive human tumor, neuroblastoma, sheds significant quantities of gangliosides in vivo (33, 34) and that these gangliosides are immunosuppressive in vitro (manuscript in preparation). Understanding exactly how tumor-derived molecules affect the extracellular environment of tumor cells may explain how tumor cells are (at the crucial initial stages of tumor formation) able to escape host defense mechanisms. Separation of the individual gangliosides making up the total tumor cell ganglioside complement (used in the present study), determination oftheir molecular structures, and testing oftheir tumormodulating activity is now necessary. This will help to answer the question of whether specific molecular details of ganglioside structure, as well as quantitative differences in ganglioside expression and shedding, are important factors in tumor formation. Finally, engineering an approach to counteract or eliminate the shed molecules holds the promise of improving the host response to tumor.
